Topical skin care composition

Details Topical skin care composition Topical skin care composition

2011-05-10

2011-05-10

Padmanabhan, Sreeni (Department: 1627)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Cyclopentanohydrophenanthrene ring system doai

C514S721000, C514S731000

Reexamination Certificate

active

07939516

ABSTRACT:
A cream base for the topical application of skin care therapeutics and a process for making the cream base. In one embodiment, the therapeutic is tretinoin, hydroquinone and fluocinolone acetonide for the treatment of hyperpigmented skin conditions, such as melasma.

REFERENCES:
patent: 1429430 (1922-10-01), Holmes et al.
patent: 2164723 (1939-07-01), Schrauth et al.
patent: 3226295 (1965-12-01), Goetz et al.
patent: 3776857 (1973-12-01), Lindner
patent: 3856934 (1974-12-01), Kligman
patent: 3906108 (1975-09-01), Felty
patent: 3966924 (1976-06-01), Fredriksson
patent: 4146499 (1979-03-01), Rosano
patent: 4254104 (1981-03-01), Suzuki
patent: 4427670 (1984-01-01), Ofuchi et al.
patent: 4603046 (1986-07-01), Georgalas et al.
patent: 4603146 (1986-07-01), Kligman
patent: 4654373 (1987-03-01), Bertelli
patent: 4737360 (1988-04-01), Allen et al.
patent: 4857321 (1989-08-01), Thomas
patent: 4992478 (1991-02-01), Geria
patent: 5145604 (1992-09-01), Neumiller
patent: 5514698 (1996-05-01), Ahmad et al.
patent: 5538737 (1996-07-01), Leonard et al.
patent: 5573781 (1996-11-01), Brown et al.
patent: 5626873 (1997-05-01), Weiner et al.
patent: 5645854 (1997-07-01), Masiz
patent: 5651991 (1997-07-01), Sugiyama et al.
patent: 5656672 (1997-08-01), Collin et al.
patent: 5660837 (1997-08-01), Lundquist
patent: 5744148 (1998-04-01), Habif et al.
patent: 5851543 (1998-12-01), Korb et al.
patent: 5935589 (1999-08-01), Mulcherjee et al.
patent: 5951993 (1999-09-01), Scholz et al.
patent: 5962512 (1999-10-01), Goupil
patent: 5972359 (1999-10-01), Sine et al.
patent: 5976555 (1999-11-01), Liu et al.
patent: 5997890 (1999-12-01), Sine et al.
patent: 6001377 (1999-12-01), SaNogueira, Jr. et al.
patent: 6030623 (2000-02-01), Meade
patent: 6080393 (2000-06-01), Liu et al.
patent: 6090395 (2000-07-01), Asmus et al.
patent: 6139824 (2000-10-01), Ribery et al.
patent: 6153657 (2000-11-01), Kisuno et al.
patent: 6174533 (2001-01-01), SaNogueira, Jr. et al.
patent: 6200964 (2001-03-01), Singleton et al.
patent: 6267985 (2001-07-01), Chen et al.
patent: 6365656 (2002-04-01), Green et al.
patent: 6383499 (2002-05-01), Lipi
patent: 6413536 (2002-07-01), Gibson et al.
patent: 6423323 (2002-07-01), Neubourg
patent: 2005/0101580 (2005-05-01), Puglia et al.
patent: 2006/0099173 (2006-05-01), Puglia et al.
patent: 2008/0007846 (2008-01-01), Wu et al.
patent: 2 833 841 (2003-06-01), None
patent: 2 833 841 (2003-06-01), None
patent: 01-203036 (1989-08-01), None
patent: 1999-0087346 (1999-12-01), None
patent: 2000-0073077 (2000-12-01), None
patent: 2001-0089781 (2001-10-01), None
patent: WO-03/055472 (2003-07-01), None
patent: WO-2004/021967 (2004-03-01), None
patent: WO 2004/037201 (2004-05-01), None
PCT International Search Report dated Aug. 27, 2004.
Lack et al., New Eng J Med, 348(11):977-85 (2003).
Lever, B Med J, 313:299-300 (1996).
Taylor et al., J Allergy Clin Immunol, 68(5):372-75 (1981).
FDA, Tri-Luma™ approval letter (Jan. 18, 2002).
Galderma Laboratories, Tri-Luma™ prescribing information (Jan. 2002).
Gilbert, B., “TriLuma Combination Effective for PIH”, Determatology Times, Sep. 1, 2005, pp. 1-2 (XP-002403792).
Cook-Bolden, F. et al., “The Use Of A Triple-Drug Combination Product and Procedures For The Treatment of Hyperpigmentary Disorders”, Cosmetic Dermatology, vol. 18, No. 8, pp. 589-594 (XP009066078), Aug. 2005.
Callender, V.D., “Acne in Ethnic Skin: Special Considerations For Therapy”, Dermatologic Therapy, 2004 No. 2, vol. 17, pp. 184-195, Blackwell Publishing, Inc., US (XP-002383242).
Goodheart, H.P., “Hyperpigmentation Disorders”, Women's Health In Primary Care, vol. 2, No. 12, Dec. 1999, pp. 923, 924, 929 (XP-002251799).
Mosby, C.V., Journal Of The American Academy Of Dermatology, vol. 52, No. 3, Mar. 2005, p. 168.
Momosawa, A. et al., “Combined Therapy Using Q-Switched Ruby Laser and Bleaching Treatment With Tretinoin And Hydroquinone For acquired Dermal Melanocytosis”, Dermatologic Surgery, Oct. 1, 2003, vol. 29, No. 10, pp. 1001-1007; Blackwell Publishing, Inc., US (XP-002383243).
Clark, J., “Cream Combo Called Melasma Drug Of Chorice”, Dermatology Times, vol. 23 No. 5, May 1, 2002, pp. 1-2 (XP008062911).
Mosby, C.V., Journal Of The American Academy Of Dermatology, vol. 52, No. 3, Mar. 2005, p. 19.
Katsambas, A.D. et al., “Depigmenting and Bleaching Agents: Coping With Hyperpigmentation”, Clinics in Dermatology, vol. 19, 2001, pp. 483-488, Elsevier Science B.V.
Kang, S. et al., “Assessment Of Adapalene Gel For The Treatment Of Actinic Keratoses And Lentigines: A Randomized Trial”, Journal Of The American Academy Of Dermatology, Jul. 2003, vol. 49, No. 1, pp. 83-90.
Milikan, L.E., “Adapalene: An Update On Newei Comparative Studies Between The Various Retinoids”, International Journal of Dermatology, vol. 39, No. 10, 2000, pp. 784-788.
Gollnick, H. et al., “Topical Therapy In Acne”, Journal Of European Academy Of Dermatology and Venereology, vol. 11, No. Supp. 1, Sep. 1998, pp. S08-S12, Elsevier Science B.V.
Torok, H.M., Hydroquinone 4%, Tretinoin 0.05%, Fluocinolone Acetonide 0.01%, Fluocinolone Acetonide 0.01%: A Safe and Efficacious 12-Month Treatment For Melasma et al., Therapeutics For Clinician, vol. 75, No. 1, Jan. 2005, pp. 57-62.
Journal Of The American Academy Of Dermatology, vol. 52, No. 3, Mar. 2005, P168.
Declaration of Sandrine Segura (Sep. 11, 2007).
Declaration of Sandrine Segura, Exhibit A (curriculum vitae of Sandrine Segura), Sep. 11, 2007.
Declaration of Sandrine Segura, Exhibit B (Tri-Luma® Cream manufacturing procedure), Sep. 11, 2007.
Declaration of Sandrine Segura, Exhibit C (Uniqema specification for Arlacel (TM) 165) Sep. 11, 2007.
Declaration of Sandrine Segura, Exhibit D (results of side-by-side study), Sep. 11, 2007.
Second Declaration of Sandrine Segura (Oct. 17, 2008).
Second Declaration of Sandrine Segura, Exhibit 1 (rheological curves), Oct. 17, 2008.
Second Declaration of Sandrine Segura, Exhibit 2 (Tri-Luma® Cream Label) Oct . 17, 2008.
Second Declaration of Sandrine Segura, Exhibit 3 (Advances in Pharmaceutical Sciences, vol. 1:22-24 (H.S. Bean, A.H. Beckett and J.E. Carless 1964).
Second Declaration of Sandrine Segura, Exhibit 4 (On-Line Medical Dictionary at http://cancerweb.ncl.ac.uk/cgi-bin/omd?query=viscosity), Oct. 17, 2008.
Declaration [of Nancy Puglia] Under 37 C.F.R. § 1.131 (Feb. 25, 2008).
Declaration [of Nancy Puglia] Under 37 C.F.R. § 1.131, Exhibit A (excerpt of batch record for Tri-Luma® Cream) (Feb. 25, 2008).
Declaration [of Nancy Puglia] Under 37 C.F.R. § 1.131 (May 1, 2009).
Declaration [of Nancy Puglia] Under 37 C.F.R. § 1.131, Exhibit 1 (excerpt of batch record for Tri-Luma® Cream) (May 1, 2009).
L'Oreal Annual Report (2002).
E. Sagarin, Cosmetics Science and Technology, p. 1004 (Interscience Publishers, Inc. 1957).
Handbook Of Pharmaceutical Excipients (3rd edition, 2000) pp. 117-120 and 537-538.
Office Action for U.S. Appl. No. 11/114,426 (Nov. 29, 2009).

Affiliated with

Also associated with

Rating

Topical skin care composition does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Topical skin care composition, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Topical skin care composition will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2691815